Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
[esophageal adenocarcinoma]
It
has
previously
been
shown
that
gefitinib-treated
patients
with
epidermal
growth
factor
receptor
(
EGFR
)
gene
amplification
or
high
polysomy
had
a
statistically
significant
improvement
in
response
,
time
to
progression
,
and
survival
in
non-
small
cell
lung
cancer
(
NSCLC
)
.
Only
few
studies
utilizing
anti-
EGFR
treatment
in
advanced
esophageal
adenocarcinomas
have
been
performed
and
the
results
have
been
heterogeneous
.
The
aim
of
this
study
was
to
evaluate
EGFR
-targeted
therapy
with
gefitinib
in
esophageal
adenocarcinoma
with
a
high
EGFR
polysomy
.
Novel
esophageal
cell
lines
PT
6216
and
LN
6216
c
were
established
from
primary
tumor
and
lymph
node
metastasis
of
a
patient
with
highly
aggressive
and
metastatic
adenocarcinoma
.
Pathological
examination
including
tumor
differentiation
and
prognostic
marker
analysis
,
immunohistochemical
EGFR
expression
analysis
,
EGFR
fluorescence
in
situ
hybridization
,
and
mutation
analysis
were
performed
.
Response
of
novel
cell
lines
to
gefitinib
treatment
was
evaluated
by
cell
proliferation
and
vitality
assays
.
Fifty
-
four
esophageal
adenocarcinoma
specimens
were
evaluated
for
EGFR
gene
copy
gain
.
The
primary
tumor
cell
line
PT
6216
and
the
lymph
node
cell
line
LN
6216
c
show
a
homogenously
high
polysomy
for
EGFR
determined
by
FISH
analysis
.
Cell
proliferation
and
vitality
are
highly
sensitive
to
the
tyrosine
kinase
inhibitor
gefitinib
compared
to
esophageal
control
cells
without
a
high
polysomy
for
EGFR
.
High
polysomy
for
EGFR
was
found
in
35
%
of
patients
.
We
show
for
the
first
time
a
significant
treatment
response
to
the
EGFR
tyrosine
kinase
inhibitor
gefitinib
in
esophageal
tumor
cells
with
a
high
polysomy
for
EGFR
,
suggesting
a
future
role
of
anti-
EGFR
therapy
for
esophageal
adenocarcinoma
patients
with
a
high
EGFR
polysomy
.
Diseases
Validation
Diseases presenting
"only few studies"
symptom
cholangiocarcinoma
esophageal adenocarcinoma
esophageal carcinoma
esophageal squamous cell carcinoma
oral submucous fibrosis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom